Abstract
Alzheimer’s disease (AD) is one of the most common neurodegenerative disorders mainly affecting elderly people. It is characterized by progressive loss of memory and cognitive function. More than 95% of AD cases are related to sporadic or late-onset AD (LOAD). The etiology of LOAD is still unclear. It has been reported that environmental factors and epigenetic alterations play a significant role in AD pathogenesis. Furthermore, recently, genome-wide association studies (GWAS) identified 10 novel risk genes: ABCA7, APOE, BIN1, CD2AP, CD33, CLU, CR1, MS4A6A, MS4A4E, and PICALM, which play an important role for LOAD. In this review, the therapeutic approaches of AD by epigenetic modifications have been discussed. Nowadays, HDAC inhibitors have clinically proven its activity for epigenetic modifications. Furthermore, we try to establish the relationship between HDAC inhibitors and above mentioned LOAD risk genes. Finally, we are hoping that this review may open new area of research for AD treatment.
About the authors
![](https://cdn.statically.io/img/dx.doi.org/document/doi/10.1515/revneuro-2017-0049/asset/graphic/j_revneuro-2017-0049_cv_001.jpg)
Harikesh Dubey holds a Master’s Degree (MPharm) in Pharmacology and has more than 5 years of research experience in the field of pharmacology and toxicology with special emphasis on behavioral neuroscience. He is currently pursuing a PhD degree at the Faculty of Medical Sciences, University of Delhi, at the Department of Pharmacology of Vallabhbhai Patel Chest Institute and has done some innovative research in the field of behavioral and cognitive sciences. He is currently involved in experimental studies in Alzheimer’s disease and has presented his research at some important scientific meetings.
![](https://cdn.statically.io/img/dx.doi.org/document/doi/10.1515/revneuro-2017-0049/asset/graphic/j_revneuro-2017-0049_cv_002.jpg)
Kavita Gulati is Professor in Pharmacology at Vallabhbhai Patel Chest Institute, Faculty of Medicine, and University of Delhi, and has more than 25 years of teaching and research experience in basic and clinical pharmacology and toxicology. She is a prolific researcher, and her work is focused on neuropharmacology and allied neurosciences with specific emphasis on neuro-immune interactions. She has been the recipient of several scientific/academic honors and awards and is considered as one of the leading exponents in her field of research. She has been a visiting scientist to several reputed universities/institutes and an invited speaker in several important international conferences across the globe. Her work has led to more than 100 publications including research papers in peer-reviewed journals, and book chapters in reference and text books.
![](https://cdn.statically.io/img/dx.doi.org/document/doi/10.1515/revneuro-2017-0049/asset/graphic/j_revneuro-2017-0049_cv_003.jpg)
Arunabha Ray is the Chair, Department of Pharmacology at Vallabhbhai Patel Chest Institute, and Dean, Faculty of Medicine, University of Delhi. He has 38 years of teaching and research experience in basic and clinical pharmacology and toxicology and his specific area of research interest is behavioral pharmacology, immunopharmacology, and CNS-immune interactions. His research expertise has been duly acknowledged at the international level and won him several awards and honors from apex scientific organizations. He has been chairperson and speaker in several prestigious scientific meetings and also a visiting faculty member at leading universities/medical institutes around the world. He has more than 150 research publications, is the author of several text and reference book chapters, is an editor of four books in his areas of expertise, and is the author of Textbook in Pharmacology.
Acknowledgments
This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. However, the authors wish to thank Mrs. Anamika Singh for literary assistance in the preparation of this article.
References
Alarcon, J.M., Malleret, G., Touzani, K., Vronskaya, S., Ishii S., Kandel, E.R., and Barco, A. (2004). Chromatin acetylation, memory, and LTP are impaired in CBP+/− mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42, 947–959.10.1016/j.neuron.2004.05.021Search in Google Scholar PubMed
Alzgene – field synopsis of genetic association studies in AD. (2011).AZLFORUM-networking for a cure. http://www.alzgene.org.Search in Google Scholar
Alzheimer’s Association. (2012). FDA approved treatments for Alzheimer’s disease, 1–3.Search in Google Scholar
Alzheimer’s Association Report. (2015). Alzheimer’s disease facts and figures. Alzheimer’s Association. Alzheimer’s Dement 11, 332–384.Search in Google Scholar
Arendash, G.W., Schleif, W., Rezai-Zadeh, K., Jackson, E.K., Zacharia, L.C., Cracchiolo, J.R., Shippy, D., and Tan, J. (2006). Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142, 941–952.10.1016/j.neuroscience.2006.07.021Search in Google Scholar PubMed
Bahari-Javan, S., Sananbenesi, F., and Fischer, A. (2014). Histone-acetylation: a link between Alzheimer’s disease and post-traumatic stress disorder? Front. Neurosci. 8, 160.10.3389/fnins.2014.00160Search in Google Scholar PubMed PubMed Central
Baig, S., Joseph, S.A., Tayler, H., Abraham, R., Owen, M.J., Williams, J., Kehoe, P.G., and Love, S. (2010). The distribution and expression of picalm in Alzheimer Disease. J. Neuropathol. Exp. Neurol. 69, 1071–1077.10.1097/NEN.0b013e3181f52e01Search in Google Scholar PubMed PubMed Central
Bali, J., Gheinani, A.H., Zurbriggen, S., and Rajendran, L. (2012). Role of genes linked to sporadic Alzheimer’s disease risk in the production of β-amyloid peptides. Proc. Natl. Acad. Sci. USA 109, 15307–15311.10.1073/pnas.1201632109Search in Google Scholar PubMed PubMed Central
Barber, R.C. (2012). The genetics of Alzheimer’s disease. Scientifica 2012, Article ID 24621, pp 14.10.6064/2012/246210Search in Google Scholar PubMed PubMed Central
Beeler, N., Riederer, B.M., Waeber, G., and Abderrahmani, A. (2009). Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes. Brain Res Bull. 80, 274–281.10.1016/j.brainresbull.2009.07.006Search in Google Scholar PubMed
Bell, R.D., Winkler, E.A., Singh, I., Sagare, A.P., Deane, R., Wu, Z., Holtzman, D.M., Betsholtz, C., Armulik, A., Sallstrom, J., Berk, B.C., and Zlokovic, B.V. (2012). Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512–516.10.1038/nature11087Search in Google Scholar PubMed PubMed Central
Bradshaw, E.M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., Korff, A. V., Alzheimer’s Disease Neuroimaging Initiative, Morris, M.C., Evans, D.A., Johnson, K., Sperling, R.A., Schneider, J.A., Bennett, D.A., and De Jager, P.L. (2013). CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat. Neurosci. 16, 848–850.10.1038/nn.3435Search in Google Scholar PubMed PubMed Central
Cacabelos, R., Martinez, R., Fernandez-Novoa, L., Carril, J.C., Lombardi, V., Carrera, I., Corzo, L., Tellado, I., Leszek, J., McKay, A., and Takeda, M. (2012). Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. Int. J. Alzheimers Dis. 2012, 518901.10.1155/2012/518901Search in Google Scholar PubMed PubMed Central
Carrasquillo, M.M., Crook, J.E., and Pedraza, O. (2015). Late-onset Alzheimer’s risk variants in memory decline, incident mild cognitive impairment, and Alzheimer’s disease. Neurobiol. Aging 36, 60–67.10.1016/j.neurobiolaging.2014.07.042Search in Google Scholar PubMed PubMed Central
Cervantes, S., Samaranch, L., Vidal-Taboada, J.M., Lamet, I., Bullido, M.J., Frank-García, A., Coria, F., Lleó, A., Clarimón, J., Lorenzo, E., et al. (2011). Genetic variation in APOE cluster region and Alzheimer’s disease risk. Neurobiol. Aging 32, 2107.e7–2107.e17.10.1016/j.neurobiolaging.2011.05.023Search in Google Scholar PubMed
Chan, G. (2014). Dissecting the role of Alzheimer’s disease susceptibility loci in primary human monocytes: a complex interplay between TREM1, TREM2 and CD33, J. Neuroimmunol. 275, 143.10.1016/j.jneuroim.2014.08.383Search in Google Scholar
Chan, S.L., Kim, W.S., Kwok, J.B., Hill, A.F., Cappai, R. Rye, K.A., and Garner, B. (2008). ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J. Neurochem. 106, 793–804.10.1111/j.1471-4159.2008.05433.xSearch in Google Scholar PubMed
Chapuis, J., Hansmannel, F., Gistelinck, M., Mounier, A., Van Cauwenberghe, C., Kolen, K.V., Geller, F., Sottejeau, Y., Harold, D., Dourlen, P., et al. (2013). Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. Mol. Psychiatry 18, 1225–1234.10.1038/mp.2013.1Search in Google Scholar PubMed PubMed Central
Chen, H., Wu, G., Jiang, Y., Feng, R., Liao, M., Zhang, L., Ma, G., Chen, Z., Zhao, B., Li, K., et al. (2015). Analyzing 54 936 samples supports the association between CD2AP rs9349407 polymorphism and Alzheimer’s disease susceptibility. Mol. Neurobiol. 52, 1–7.10.1007/s12035-014-8834-2Search in Google Scholar PubMed
Chittur, S.V., Sangster-Guity, N., and McCormick, P.J. (2008). Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism. BMC Genomics 9, 507.10.1186/1471-2164-9-507Search in Google Scholar PubMed PubMed Central
Chung, S.J., Kim, M.J., Kim, Y.J., Kim, J., You, S., Jang, E.H., Kim, S.Y., and Lee, J.H. (2014). CR1, ABCA7, and APOE genes affect the features of cognitive impairment in Alzheimer’s disease. J. Neurol. Sci. 339, 91–96.10.1016/j.jns.2014.01.029Search in Google Scholar PubMed
Dagnas, M., Guillou, J.L., Prevot, T., and Mons, N. (2013) HDAC inhibition facilitates the switch between memory systems in young but not aged mice. J. Neurosci. 33, 1954–1963.10.1523/JNEUROSCI.3453-12.2013Search in Google Scholar PubMed PubMed Central
Debnath, I., Roundy, K.M., Weis, J.J., and Weis, J.H. (2007). Defining in vivo transcription factor complexes of the murine CD21 and CD23 genes. J. Immunol. 178, 7139–7150.10.4049/jimmunol.178.11.7139Search in Google Scholar PubMed
De Paula, V.D.R., Guimaraes, F.M., Diniz, B.S., and Forlenza, O.V. (2009). Neurobiological pathways to Alzheimer’s disease, Amyloid-beta, Tau protein or both? Dement. Neuropsychol. 3, 188–194.Search in Google Scholar
Dinarello, C.A., Fossati, G., and Mascagni, P. (2011). Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol. Med. 17, 333–352.10.2119/molmed.2011.00116Search in Google Scholar PubMed PubMed Central
Durham, B. (2012). Novel histone deacetylase (HDAC) inhibitors with improved selectivity for HDAC2 and 3 protect against neural cell death. Biosci. Horizons 5, 1–7.10.1093/biohorizons/hzs003Search in Google Scholar
Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., Runz, H., Kuhl, S., Bertsch, T., von Bergmann, K., et al. (2001). Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Aβ 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98, 5856–5861.10.1073/pnas.081620098Search in Google Scholar PubMed PubMed Central
Ferrari, R., Moreno, J.H., Minhajuddin, A.T., O’Bryant, S.E., Reisch, J.S., Barber, R.C., and Momeni, P. (2012). Implication of common and disease specific variants in CLU, CR1, and PICALM. Neurobiol. Aging 33, 1846.e7–1846.e18.10.1016/j.neurobiolaging.2012.01.110Search in Google Scholar PubMed
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., and Tsai, L.H. (2007). Recovery of learning and memory is associated with chromatin remodelling. Nature 447, 178–182.10.1038/nature05772Search in Google Scholar PubMed
Fujita, Y., Morinobu, S., Takei, S., Fuchikami, M., Matsumoto, T., and Yamamoto, S. (2012). Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene. J. Psychiatr. Res. 46, 635–643.10.1016/j.jpsychires.2012.01.026Search in Google Scholar PubMed
Gao, Y.S., Hubbert, C.C., Lu, J., Lee, Y.S, Lee, J.Y., and Yao, T.P. (2007). Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol. Cell. Biol. 27, 8637–8647.10.1128/MCB.00393-07Search in Google Scholar PubMed PubMed Central
Glennon, E.B., Whitehouse, I.J., Miners, J.S., Kehoe, P.G., Love, S., Kellett, K.A., and Hooper, N.M. (2013). BIN1 is decreased in sporadic but not familial Alzheimer’s disease or in aging. PLoS One 8, e78806.10.1371/journal.pone.0078806Search in Google Scholar PubMed PubMed Central
Golde, T.E., Streit, W.J., and Chakrabarty, P. (2013). Alzheimer’s disease risk alleles in TREM2 illuminate innate immunity in Alzheimer’s disease. Alzheimers Res. Ther. 5, 24.10.1186/alzrt178Search in Google Scholar PubMed PubMed Central
Goldberg, A.D., Allis, C.D., and Bernstein, E. (2007). Epigenetics: a landscape takes shape. Cell 128, 635–638.10.1016/j.cell.2007.02.006Search in Google Scholar PubMed
Gomez-Ramirez, J. and Wu, J. (2014). Network-based biomarkers in Alzheimer’s disease: review and future directions. Front. Aging Neurosci. 6, 12.10.3389/fnagi.2014.00012Search in Google Scholar PubMed PubMed Central
Graff, J., Rei, D., Guan, J.S., Wang, W.Y., Seo, J., Hennig, K.M., Nieland, T.J., Fass, D.M., Kao, P.F., Kahn, M., et al. (2012). An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483, 222–226.10.1038/nature10849Search in Google Scholar PubMed PubMed Central
Graff, J., Joseph, N., Horn, M.E., Samiei, A., Meng, J., Seo, J., Rei, D., Bero, A.W., Phan, T.X., Wagner, F., et al. (2014). Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 156, 261–276.10.1016/j.cell.2013.12.020Search in Google Scholar PubMed PubMed Central
Green, A.E., Gray, J.R., Deyoung, C.G., Mhyre, T.R., Padilla, R., Dibattista, A.M., and William Rebeck, G. (2014). A combined effect of two Alzheimer’s risk genes on medial temporal activity during executive attention in young adults. Neuropsychologia 56, 1–8.10.1016/j.neuropsychologia.2013.12.020Search in Google Scholar PubMed PubMed Central
Griciuc, A., Serrano-Pozo, A., Parrado, A.R., Lesinski, A.N., Asselin, C.N., Mullin, K., Hooli, B., Choi, S.H., Hyman, B.T., and Tanzim R.E. (2013). Alzheimer’s disease risk gene cd33 inhibits microglial uptake of amyloid β. Neuron 78, 631–643.10.1016/j.neuron.2013.04.014Search in Google Scholar PubMed PubMed Central
Grimm, M.O., Zimmer, V.C., Lehmann, J., Grimm, H.S., and Hartmann, T. (2013). The impact of cholesterol, DHA, and sphingolipids on Alzheimer’s disease. Biomed. Res. Int. 2013, 814390.10.1155/2013/814390Search in Google Scholar PubMed PubMed Central
Guan, J.S., Haggarty, S.J., Giacometti, E., Dannenberg, J.H., Joseph, N., Gao, J., Nieland, T.J., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009). HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55–56.10.1038/nature07925Search in Google Scholar PubMed PubMed Central
Guerreiro, R., Bras, J., and Hardy, J. (2013). SnapShot: genetics of Alzheimer’s disease. Cell 155, 968–968.e1.10.1016/j.cell.2013.10.037Search in Google Scholar PubMed
Guillot-Sestier, M.V. and Town, T. (2013). Innate immunity in Alzheimer’s disease: a complex affair. CNS Neurol. Disord. Drug Targets 12, 593–607.10.2174/1871527311312050008Search in Google Scholar PubMed PubMed Central
Hassa, P.O., Haenni, S.S., Buerki, C., Meier, N.I., Lane, W.S., Owen, H., Gersbach, M., Imhof, R., and Hottiger, M.O. (2005). Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-κB-dependent transcription. J. Biol. Chem. 280, 40450–40464.10.1074/jbc.M507553200Search in Google Scholar PubMed
Hazrati, L.N., Van Cauwenberghe, C., Brooks, P.L., Brouwers, N., Ghani, M., Sato, C., Cruts, M., Sleegers, K., St. George-Hyslop, P., Van Broeckhoven, C., et al. (2012). Genetic association of CR1 with Alzheimer’s disease: a tentative disease mechanism. Neurobiol. Aging 33, 2949.e5–2949.e12.10.1016/j.neurobiolaging.2012.07.001Search in Google Scholar PubMed
Heneka, M.T., Kummer, M.P., and Latz, E. (2014). Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14, 463–477.10.1038/nri3705Search in Google Scholar PubMed
Heneka, M.T., Golenbock, D.T., and Latz, E. (2015). Innate immunity in Alzheimer’s disease. Nat. Immunol. 16, 229–236.10.1038/ni.3102Search in Google Scholar PubMed
Holler, C.J., Davis, P.R., Beckett, T.L., Platt, T.L., Webb, R.L., Head, E., and Murphy, M.P. (2014). Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer’s disease brain and correlates with neurofibrillary tangle pathology. J. Alzheimers Dis. 42, 1221–1227.10.3233/JAD-132450Search in Google Scholar PubMed PubMed Central
Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.C., Carrasquillo, M.M., Abraham, R., Hamshere, M.L., Pahwa, J.S., Moskvina, V., et al. (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat. Genet. 43, 429–435.10.1038/ng.803Search in Google Scholar PubMed PubMed Central
Holtzman, D.M., Herz, J., and Bu, G. (2012). Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2, a006312.10.1101/cshperspect.a006312Search in Google Scholar PubMed PubMed Central
Iwata, A. and Iwatsubo, T. (2013). Disease-modifying therapy for Alzheimer’s disease: challenges and hopes. Neurol. Clin. Neurosci. 1, 49–54.10.1002/ncn3.20Search in Google Scholar
Jeng, A., Karch, C., Nowotny, P., Cruchaga, C., and Goate, A. (2012). ABCA7 and MS4A6A expression are upregulated in Alzheimer’s disease brains. Alzheimer’s Dement. 8, P663.10.1016/j.jalz.2012.05.1787Search in Google Scholar
Jiang, T., Yu, J.T., Hu, N., Tan, M.S., Zhu, X.C., and Tan, L. (2014). CD33 in Alzheimer’s disease. Mol. Neurobiol. 49, 529–535.10.1007/s12035-013-8536-1Search in Google Scholar PubMed
Kamboh, M.I., Minster, R.L., Demirci, F.Y., Ganguli, M., DeKosky, S.T., Lopez, O.L., and Barmad, M.M. (2012). Association of CLU and PICALM variants with Alzheimer’s disease. Neurobiol. Aging 33, 518–521.10.1016/j.neurobiolaging.2010.04.015Search in Google Scholar PubMed PubMed Central
Kanai, M., Tong, W.M., Sugihara, E., Wang, Z.Q., Fukasawa, K., and Miwa, M. (2003). Involvement of poly(ADP-Ribose) polymerase 1 and poly(ADP-Ribosyl)ation in regulation of centrosome function. Mol. Cell. Biol. 23, 2451–2462.10.1128/MCB.23.7.2451-2462.2003Search in Google Scholar PubMed PubMed Central
Karch, C. M., Jeng, A.T., Nowotny, P., Cady, J., Cruchaga, C., and Goate, A.M. (2012). Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains. PLoS One 7, e50976.10.1371/journal.pone.0050976Search in Google Scholar PubMed PubMed Central
Kazantsev, A.G. and Thompson, L.M. (2008). Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Disc. 7, 854–868.10.1038/nrd2681Search in Google Scholar PubMed
Khera, R. and Das, N. (2009). Complement receptor 1: disease associations and therapeutic implications. Mol. Immunol. 46, 761–772.10.1016/j.molimm.2008.09.026Search in Google Scholar PubMed PubMed Central
Kilgore, M., Miller, C.A., Fass, D.M., Hennig, K.M., Haggarty, S.J., Sweatt, J.D., and Rumbaugh, G. (2010). Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharma cology 35, 870–880.10.1038/npp.2009.197Search in Google Scholar PubMed PubMed Central
Kim, M.Y., Zhang, T., and Kraus, W.L. (2005a). Poly(ADP-ribosyl)ation by PARP-1: PAR-laying’ NAD+ in to a nuclear signal. Genes Dev. 19, 1951–1967.10.1101/gad.1331805Search in Google Scholar PubMed
Kim, Y.J., Guo, S., Park, J.W., Bae, E.K., Ahn, K.-S., Kim, I., Lee, J.-S., Lee, Y.Y., Park, S., Kim, B.K., et al. (2005b). Novel synthetic histone deacetylase inhibitor (SK-7041) potently inhibits proliferation in acute myeloid leukemia cell lines. Blood 106, 4407.10.1182/blood.V106.11.4407.4407Search in Google Scholar
Kim, W.S., Li, H., Ruberu, K., Chan, S., Elliott, D.A., Low, J.K., Cheng, D., Karl, T., and Garner, B. (2013). Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer’s disease. J. Neurosci. 33, 4387–4394.10.1523/JNEUROSCI.4165-12.2013Search in Google Scholar PubMed PubMed Central
Kitazawa, M., Oddo, S., Yamasaki, T.R., Green, K.R., and LaFerla, F.M. (2005). Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease. J. Neurosci. 25, 8843–8853.10.1523/JNEUROSCI.2868-05.2005Search in Google Scholar PubMed PubMed Central
Kojro, E., Gimpl, G., Lammich, S., Marz, W., and Fahrenholz, F. (2001). Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl. Acad. Sci. USA 98, 5815–5820.10.1073/pnas.081612998Search in Google Scholar PubMed PubMed Central
Kok, E.H., Luoto, T., Haikonen, S., Goebeler, S., Haapasalo, H., and Karhunen, P.J. (2011). CLU, CR1 and PICALM genes associate with Alzheimer’s-related senile plaques. Alzheimer’s Res. Ther. 3, 12.10.1186/alzrt71Search in Google Scholar PubMed PubMed Central
Koltai, T. (2014). Clusterin: a key player in cancer chemoresistance and its inhibition. Onco. Targets Ther. 7, 447–456.10.2147/OTT.S58622Search in Google Scholar PubMed PubMed Central
Korwek, K.M., Trotter, J.H., Ladu, M.J., Sullivan, P.M., and Weeber, E.J. (2009). ApoE isoform-dependent changes in hippocampal synaptic function. Mol. Neurodegener. 4, 21.10.1186/1750-1326-4-21Search in Google Scholar PubMed PubMed Central
Korzus, E., Rosenfeld, M.G., and Mayford, M. (2004). CBP Histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42, 961–972.10.1016/j.neuron.2004.06.002Search in Google Scholar PubMed PubMed Central
Kosugi, H., Towatari, M., Hatano, S., Kitamura, K., Kiyoi, H., Kinoshita, T., Tanimoto, M., Murate, T., Kawashima, K., Saito, H., et al. (1999). Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 13, 1316–1324.10.1038/sj.leu.2401508Search in Google Scholar PubMed
Kroesen, M., Gielen, P., Brok, I.C., Armandari, I., Hoogerbrugge, P.M., and Adema G.J. (2014). HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget 5, 6558–6572.10.18632/oncotarget.2289Search in Google Scholar PubMed PubMed Central
Kurdistani, S.K. and Grunstein, M. (2003). Histone acetylation and deacetylation in yeast. Nat. Rev. Mol. Cell Biol. 4, 276–284.10.1038/nrm1075Search in Google Scholar PubMed
Lambert, J.C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M.J., Tavernier, B., et al. (2009). Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat. Genet. 41, 1094–1099.10.1038/ng.439Search in Google Scholar PubMed
Lambert, J.C., Zelenika, D., Hiltunen, M., Chouraki, V., Combarros, O., Bullido, M.J., Tognoni, G., Fiévet, N., Boland, A., Arosio, B., et al. (2011). Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol. Aging 32, 756.e11–756.e15.10.1016/j.neurobiolaging.2010.11.022Search in Google Scholar PubMed
Lee, J. H., Cheng, R., Barral, S., Reitz, C., Medrano, M., Lantigua, R., Jiménez-Velazquez, I.Z., Rogaeva, E., St. George-Hyslop, P.H., and Mayeux, R. (2011). Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch. Neurol. 68, 320–328.10.1001/archneurol.2010.292Search in Google Scholar PubMed PubMed Central
Levenson, J.M., O’Riordan, K.J., and Brown, K.D. (2004) Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem. 279, 40545–40559.10.1074/jbc.M402229200Search in Google Scholar PubMed
Liao, Y.C., Lee, W.J., Hwang, J.P., Wang, Y.F., Tsai, C.F., Wang, P.N., Wang, S.J., and Fuh, J.L. (2014). ABCA7 gene and the risk of Alzheimer’s disease in Han Chinese in Taiwan. Neurobiol. Aging 35, 2423.e7–2423.e13.10.1016/j.neurobiolaging.2014.05.009Search in Google Scholar
Liao, F., Jiang, H., Srivatsan, S., Xiao, Q., Lefton, K.B., Yamada, K., Mahan, T.E., Lee, J.M., Shaw, A.S., and Holtzman, D.M. (2015). Effects of CD2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model. Mol. Neurodegener. 10, 12.10.1186/s13024-015-0006-ySearch in Google Scholar
Lillico, R., Sobral, M.G., Stesco, N., and Lakowski, T.M. (2016). HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases. J. Proteomics. 133, 125–133.10.1016/j.jprot.2015.12.018Search in Google Scholar PubMed
Limpeanchob, N., Jaipan, S., Rattanakaruna, S., Phrompittayarat, W., and Ingkaninan, K. (2008). Neuroprotective effect of Bacopa monnieri on β-amyloid-induced cell death in primary cortical culture. J. Ethnopharmacol. 120, 112–117.10.1016/j.jep.2008.07.039Search in Google Scholar PubMed
Ling, I.F., Bhongsatiern, J., Simpson, J.F., Fardo, D.W., and Estus, S. (2012). Genetics of clusterin isoform expression and Alzheimer’s disease risk. PLoS One 7, e33923.10.1371/journal.pone.0033923Search in Google Scholar PubMed
Lista, S., Garaci, F.G., Toschi, N., and Hampel, H. (2013). Imaging epigenetics in Alzheimer’s disease. Curr. Pharm. Des. 19, 6393–6415.10.2174/13816128113199990370Search in Google Scholar PubMed
Liu, G., Zhang, L., Feng, R., Liao, M., Jiang, Y., Chen, Z., Zhao, B., and Li, K. (2013). Lack of association between PICALM rs3851179 polymorphism and Alzheimer’s disease in Chinese population and APOEε4-negative subgroup. Neurobiol. Aging 34, 1310.e9–1310.e10.10.1016/j.neurobiolaging.2012.08.015Search in Google Scholar
Logge, W., Cheng, D., Chesworth, R. Bhatia, S., Garner, B., Kim, W.S., and Karl, T. (2012). Role of Abca7 in mouse behaviours relevant to neurodegenerative diseases. PLoS One 7, e45959.10.1371/journal.pone.0045959Search in Google Scholar PubMed
Lovestone, S., Davis, D.R., Webster, M.T., Kaech, S., Brion, J.P., Matus, A., and Anderton, B.H. (1999). Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol. Psychiatr. 45, 995–1003.10.1016/S0006-3223(98)00183-8Search in Google Scholar
Malik, M., Simpson, J.F., Parikh, I., Wilfred, B.R., Fardo, D.W., Nelson, P.T., and Estus, S. (2013). CD33 Alzheimer’s risk-altering polymorphism, CD33 expression, and exon 2 splicing. J. Neurosci. 33, 13320–13325.10.1523/JNEUROSCI.1224-13.2013Search in Google Scholar PubMed
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., and Kivipelto, M. (2010). Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 9, 702–716.10.1016/S1474-4422(10)70119-8Search in Google Scholar PubMed
Martiskainen, H., Viswanathan, J., Nykanen, N.P., Kurki, M., Helisalmi, S., Natunen, T., Sarajarvi, T., Kurkinen, K.M., Pursiheimo, J.P., Rauramaa, T., et al. (2015). Transcriptomics and mechanistic elucidation of Alzheimer’s disease risk genes in the brain and in vitro models. Neurobiol. Aging 36, 1221.e15–28.10.1016/j.neurobiolaging.2014.09.003Search in Google Scholar PubMed
Mehta, M., Adem, A., and Sabbagh, M. (2012). New acetylcholinesterase inhibitors for Alzheimer’s disease. Int. J. Alzheimers Dis. 2012, 728983.10.1155/2012/728983Search in Google Scholar PubMed PubMed Central
Mengel-From, J., Christensen, K., McGue, M., and Christiansen, L. (2011). Genetic variations in the CLU and PICALM genes are associated with cognitive function in the oldest old. Neurobiol. Aging 32, 554.e7–554.e11.10.1016/j.neurobiolaging.2010.07.016Search in Google Scholar PubMed PubMed Central
Nencioni, A., Beck, J., Werth, D., Grunebach, F., Patrone, F., Ballestrero, A., and Brossart, P. (2007). Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer. Res. 13, 3933–3941.10.1158/1078-0432.CCR-06-2903Search in Google Scholar PubMed
Nuutinen, T., Suuronen, T., Kyrylenko, S., Huuskonen, J., and Salminen, A. (2005). Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Neurochem. Int. 47, 528–538.10.1016/j.neuint.2005.07.007Search in Google Scholar PubMed
Nuutinen, T., Suuronen, T., Kauppinen, A., and Salminen, A. (2009). Clusterin: a forgotten player in Alzheimer’s disease. Brain Res. Rev. 61, 89–104.10.1016/j.brainresrev.2009.05.007Search in Google Scholar PubMed
Nygaard, H.B. (2013). Current and emerging therapies for Alzheimer’s disease. Clin. Ther. 35, 1480–1489.10.1016/j.clinthera.2013.09.009Search in Google Scholar PubMed
Osborn, G.G. and Saunders, A.V. (2010). Current treatments for patients with Alzheimer disease. J. Am. Osteopath. Assoc. 110(9 Suppl. 8), S16–S26.Search in Google Scholar
Parikh, I., Fardo, D.W., and Estus, S. (2014). Genetics of expression and Alzheimer’s disease. PLoS One 9, e91242.10.1371/journal.pone.0091242Search in Google Scholar PubMed PubMed Central
Peserico, A. and Simone, C. (2011). Physical and functional HAT/HDAC interplay regulates protein acetylation balance. J. Biomed. Biotechnol. 2011, 371832.10.1155/2011/371832Search in Google Scholar PubMed PubMed Central
Proitsi, P., Lee, S.H., Lunnon, K., Keohane, A., Powell, J., Troakes, C., Al-Sarraj, S., Furney, S., Soininen, H., Kłoszewska, I., et al. (2014). Alzheimer’s disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood. Neurobiol. Aging 35, 279–290.10.1016/j.neurobiolaging.2013.08.002Search in Google Scholar PubMed
Ramanan, V.K. and Saykin, A.J. (2013). Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer’s disease, Parkinson’s disease, and related disorders. Am. J. Neurodegener. Dis. 2, 145–175.Search in Google Scholar PubMed
Rao, A.T., Degnan, A.J., and Levy, L.M. (2014). Genetics of Alzheimer Disease. Am. J. Neuroradiol. 35, 457–458.10.3174/ajnr.A3545Search in Google Scholar PubMed PubMed Central
Reinvang, I., Espeseth, T., and Westlye, L.T. (2013). APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer’s disease. Neurosci. Biobehav. Rev. 37, 1322–1335.10.1016/j.neubiorev.2013.05.006Search in Google Scholar PubMed
Reitz, C., Jun, G., Naj, A., Rajbhandary, R., Vardarajan, B.N., Wang, L.-S., Valladares, O., Lin, C.-F., Larson, E.B., Graff-Radford, N.R., et al. (2013). Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ε4, and the risk of late-onset Alzheimer disease in African Americans. J. Am. Med. Assoc. 309, 1483–1492.10.1001/jama.2013.2973Search in Google Scholar PubMed PubMed Central
Rodriguez-Rodriguez, E., Sánchez-Juan, P., Vazquez-Higuera, J.L., Mateo, I., Pozueta, A., Berciano, J., Cervantes, S., Alcolea, D., Martinez-Lage, P., Clarimon, J., et al. (2013). Genetic risk score predicting accelerated progression from mild cognitive impairment to Alzheimer’s disease. J. Neural Transm. 120, 807–812.10.1007/s00702-012-0920-xSearch in Google Scholar PubMed
Roussotte, F.F., Gutman, B.A., Madsen, S.K., Colby, J.B., and Thompson, P.M. (2014). Combined effects of Alzheimer risk variants in the CLU and ApoE genes on ventricular expansion patterns in the elderly. J. Neurosci. 34, 6537–6545.10.1523/JNEUROSCI.5236-13.2014Search in Google Scholar PubMed PubMed Central
Salloway, S. and Correia, S. (2009). Alzheimer disease: time to improve its diagnosis and treatment. Cleve. Clin. J. Med. 76, 49–58.10.3949/ccjm.76a.072178Search in Google Scholar PubMed
Satoh, K., Abe-Dohmae, S., Yokoyama, S., St. George-Hyslop, P., and Fraser, P. (2012). ATP-binding cassette transporter A7 (ABCA7) effects on amyloid processing and relevance to Alzheimer’s disease. Alzheimer’s Dement. 8, P473.10.1016/j.jalz.2012.05.1272Search in Google Scholar
Schwab, J. and Illges, H. (2001). Regulation of CD21 expression by DNA methylation and histone deacetylation. Int. Immunol. 13, 705–710.10.1093/intimm/13.5.705Search in Google Scholar PubMed
Shuttleworth, S.J., Bailey, S.G., and Townsend, P.A. (2010). Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr. Drug Targets 11, 1430–1438.10.2174/1389450111009011430Search in Google Scholar PubMed
Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C.G., and Simons, K. (1998). Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. USA 95, 6460–6464.10.1073/pnas.95.11.6460Search in Google Scholar PubMed PubMed Central
Smits, L.L., Pijnenburg, Y.A., van der Vlies, A.E., Koedam, E.L., Bouwman, F.H., Reuling, I.E., Scheltens, P., and van der Flier, W.M. (2015). Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains. Eur. Neuropsychopharmacol. 25, 1010–1017.10.1016/j.euroneuro.2015.03.014Search in Google Scholar PubMed
Steinberg, S., Stefansson, H., Jonsson, T., Johannsdottir, H., Ingason, A., Helgason, H., Sulem, P., Magnusson, O.T., Gudjonsson, S.A., Unnsteinsdottir, U., et al. (2015). Loss-of-function variants in ABCA7 confer risk of Alzheimer’s disease. Nat. Genet. 47, 445–447.10.1038/ng.3246Search in Google Scholar PubMed
Sun, L., Tan, M.S., Hu, N., Yu, J.T., and Tan, L. (2013). Exploring the value of plasma BIN1 as a potential biomarker for Alzheimer’s disease. J. Alzheimers Dis. 37, 291–295.10.3233/JAD-130392Search in Google Scholar PubMed
Tan, M.S., Yu, J.T., and Tan, L. (2013). Bridging integrator 1 (BIN1): form, function, and Alzheimer’s disease. Trends Mol. Med. 19, 594–603.10.1016/j.molmed.2013.06.004Search in Google Scholar PubMed
Tan, M.S., Yu, J.T., Jiang, T., Zhu, X.C., Guan, H.S., and Tan, L. (2014). Genetic variation in BIN1 gene and Alzheimer’s disease risk in Han Chinese individuals. Neurobiol. Aging 35, 1781.e1–1781.e8.10.1016/j.neurobiolaging.2014.01.151Search in Google Scholar PubMed
Talwar, P., Sinha, J., Grover, S., Rawat, C., Kushwaha, S., Agarwal, R., Taneja, V., and Kukreti, R. (2015). Dissecting complex and multifactorial nature of Alzheimer’s disease pathogenesis: a clinical, genomic, and systems biology perspective. Mol. Neurobiol. 1–32.10.1007/s12035-015-9390-0Search in Google Scholar PubMed
Tanida, S., Mizoshita, T., Ozeki, K., Tsukamoto, H., Kamiya, T., Kataoka, H., Sakamuro, D., and Joh, T. (2012). Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int. J. Surg. Oncol. 2012, 862879.10.1155/2012/862879Search in Google Scholar PubMed PubMed Central
Thomas, R., Gerrish, A., Henson, A., Jones, L., Williams, J., and Kidd, E. (2014). Decreasing PICALM expression alters the amyloidogenic processing of amyloid precursor protein. Alzheimer’s Assoc. Int. Conf. 10, P334–P335.10.1016/j.jalz.2014.05.325Search in Google Scholar
Tian, Y., Chang, J.C., Fan, E.Y., Flajolet, M., and Greengard, P. (2013). Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer’s APP-CTF for terminal degradation via autophagy. Proc. Natl. Acad. Sci. USA 110, 17071–17076.10.1073/pnas.1315110110Search in Google Scholar
U.S. FDA U.S. Department of health and human services food and drug administration. (2016). Approved drug products with therapeutic equivalence evaluations. 36th edition (www.fda.gov/downloads/drugs/deve;lopmentapprovalprocess/ucm071436.pdf).Search in Google Scholar
Van Cauwenberghe, C., Bettens, K., Engelborghs, S., Vandenbulcke, M., Van Dongen, J., Vermeulen, S., Vandenberghe, R., De Deyn, P.P., Van Broeckhoven, C., and Sleegers, K. (2013). Complement receptor 1 coding variant p.Ser1610Thr in Alzheimer’s disease and related endophenotypes. Neurobiol. Aging 34, 2235.e1–2235.e6.10.1016/j.neurobiolaging.2013.03.008Search in Google Scholar
Vasquez, J. B., Fardo, D.W., and Estus, S. (2013). ABCA7 expression is associated with Alzheimer’s disease polymorphism and disease status. Neurosci. Lett. 556, 58–62.10.1016/j.neulet.2013.09.058Search in Google Scholar PubMed
Vecsey, C.G., Hawk, J.D., Lattal, K.M., Stein, J.M., Fabian, S.A., Attner, M.A., Cabrera, S.M., McDonough, C.B., Brindle, P.K., Abel, T., et al. (2007). Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB: CBP-dependent transcriptional activation. J. Neurosci. 27, 6128–6140.10.1523/JNEUROSCI.0296-07.2007Search in Google Scholar PubMed
Verghese, P.B., Castellano, J.M., and Holtzman, D.M. (2011). Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol. 10, 241–252.10.1016/S1474-4422(10)70325-2Search in Google Scholar PubMed
Wang, J., Yu, J.T., Tan, M.S., Jiang, T., and Tan, L. (2013). Epigenetic mechanisms in Alzheimer’s disease: implications for pathogenesis and therapy. Ageing Res. Rev. 12, 1024–1041.10.1016/j.arr.2013.05.003Search in Google Scholar PubMed
Wirz, K.T., Keitel, S., Swaab, D.F., Verhaagen, J., and Bossers, K. (2014). Early molecular changes in Alzheimer disease: can we catch the disease in its presymptomatic phase? J. Alzheimer’s Dis. 38, 719–740.10.3233/JAD-130920Search in Google Scholar PubMed
Wood, M.A., Hawk, J.D., and Abel, T. (2006). Combinatorial chromatin modifications and memory storage: a code for memory? Learn. Mem. 13, 241–244.10.1101/lm.278206Search in Google Scholar PubMed PubMed Central
Xiao, Q., Gil, S.C., Yan, P., Wang, Y., Han, S., Gonzales, E., Perez, R., Cirrito, J.R., and Lee, J.M. (2012). Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. J. Biol. Chem. 287, 21279–21289.10.1074/jbc.M111.338376Search in Google Scholar PubMed PubMed Central
Xu, K., Dai, X.L., Huang, H.C., and Jiang, Z.F. (2011). Targeting HDACs: a promising therapy for Alzheimer’s disease. Oxid. Med. Cell. Longev. 2011, 143269.10.1155/2011/143269Search in Google Scholar PubMed PubMed Central
Xu, X., Kozikowski, A.P., and Pozzo-Miller, L. (2014). A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome. Front. Cell Neurosci. 8, 68.10.3389/fncel.2014.00068Search in Google Scholar PubMed PubMed Central
Yan, X. X., Ma, C., Gai, W. P., Cai, H., and Luo, X. G. (2014). Can BACE1 Inhibition Mitigate Early Axonal Pathology in Neurological Diseases? J. Alzheimer’s Dis. 38, 705–718.10.3233/JAD-131400Search in Google Scholar PubMed PubMed Central
Yang, S.S., Zhang, R., Wang, G., and Zhang, Y. (2017). The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer’s disease. Transl. Neurodegener. 6, 19.10.1186/s40035-017-0089-1Search in Google Scholar PubMed PubMed Central
Yu, J.T. and Tan, L. (2012). The role of clusterin in Alzheimer’s disease: pathways, pathogenesis, and therapy. Mol. Neurobiol. 45, 314–326.10.1007/s12035-012-8237-1Search in Google Scholar PubMed
Yu, J.T., Li, L., Zhu, Q.X., Zhang, Q., Zhang, W, Wu, Z.C., Guan, J., and Tan, L. (2010). Implication of CLU gene polymorphisms in Chinese patients with Alzheimer’s disease. Clin. Chim. Acta 411, 1516–1519.10.1016/j.cca.2010.06.013Search in Google Scholar PubMed
Zabel, M.D., Weis, J.J., and Weis, J.H. (1999). Lymphoid transcription of the murine CD21 gene is positively regulated by histone acetylation. J. Immunol. 163, 2697–2703.10.4049/jimmunol.163.5.2697Search in Google Scholar PubMed
Zhang, B., Gaiteri, C., Bodea, L.G., Wang, Z., McElwee, J., Podtelezhnikov, A.A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013). Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 153, 707–720.10.1016/j.cell.2013.03.030Search in Google Scholar PubMed PubMed Central
Zhu, X.C., Yu, J.T., Jiang, T., Wang, P., Cao, L., and Tan, L. (2015). CR1 in Alzheimer’s disease. Mol. Neurobiol. 51, 753–765.10.1007/s12035-014-8723-8Search in Google Scholar PubMed
©2018 Walter de Gruyter GmbH, Berlin/Boston